Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trialResearch in context

Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trialResearch in context

Summary: Background: Frontotemporal dementia (FTD) is a common form of dementia with no approved pharmacological treatment. Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. Here we aimed at investigating the clinical impact of treatment with dopaminergic...

Full description

Saved in:
Bibliographic Details
Main Authors: Giacomo Koch, Martina Assogna, Yasmine Gadola, Antonella Alberici, Francesco Di Lorenzo, Sonia Bonnì, Ilaria Borghi, Emanuele Cerulli Irelli, Lucia Mencarelli, Michele Maiella, Romina Esposito, Elias Paolo Casula, Valentina Pezzopane, Alessia D'Acunto, Francesca Candeo, Matteo Ferraresi, Gisella Guerrera, Luca Battistini, Enrico Premi, Valeria Bracca, Silvia Lucchini, Francesco Bertagna, Pasquale Romano, Andrea Ludovici, Antonio Daniele, Caterina Motta, Clarissa Ferrari, Alessandro Martorana, Barbara Borroni
Format: Article
Language:English
Published: Elsevier 2025-10-01
Series:The Lancet Regional Health. Europe
Subjects:
Frontotemporal dementia
Rotigotine
Executive function
Neurotransmission deficit
Dopamine
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776225002017
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666776225002017

Similar Items